Squarepoint
ANIK icon

Squarepoint’s Anika Therapeutics ANIK Stock Holding History

Squarepoint’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Buy
+18,751
New +$278K ﹤0.01% 3877
2025
Q1 		– Sell
-12,859
Closed -$212K – 4525
2024
Q4 		$212K Buy
+12,859
New +$254K ﹤0.01% 4429
2024
Q3 		– Sell
-21,648
Closed -$548K – 4076
2024
Q2 		$548K Sell
21,648
-30,809
-59% -$798K ﹤0.01% 3011
2024
Q1 		$1.33M Sell
52,457
-6,098
-10% -$148K ﹤0.01% 2367
2023
Q4 		$1.33M Buy
58,555
+38,835
+197% +$804K ﹤0.01% 2314
2023
Q3 		$367K Buy
+19,720
New +$409K ﹤0.01% 3017
2022
Q2 		– Sell
-19,288
Closed -$484K – 2855
2022
Q1 		$484K Buy
+19,288
New +$588K ﹤0.01% 2027
2021
Q4 		– Sell
-4,921
Closed -$209K – 3139
2021
Q3 		$209K Sell
4,921
-7,015
-59% -$289K ﹤0.01% 2463
2021
Q2 		$517K Buy
11,936
+6,074
+104% +$259K ﹤0.01% 2104
2021
Q1 		$239K Buy
5,862
+489
+9% +$18.5K ﹤0.01% 2581
2020
Q4 		$243K Buy
+5,373
New +$204K ﹤0.01% 2370
2020
Q1 		– Sell
-28,153
Closed -$1.46M – 1836
2019
Q4 		$1.46M Buy
28,153
+13,545
+93% +$787K 0.01% 1088
2019
Q3 		$802K Buy
+14,608
New +$750K 0.01% 1375
2019
Q2 		– Sell
-9,800
Closed -$296K – 2346
2019
Q1 		$296K Sell
9,800
-11,763
-55% -$403K ﹤0.01% 1778
2018
Q4 		$725K Buy
+21,563
New +$778K 0.01% 1057
2018
Q2 		– Sell
-10,536
Closed -$524K – 1730
2018
Q1 		$524K Buy
10,536
+4,026
+62% +$227K 0.01% 1075
2017
Q4 		$351K Sell
6,510
-527
-7% -$29.2K 0.01% 1407
2017
Q3 		$408K Buy
+7,037
New +$368K 0.01% 1051
2016
Q3 		– Sell
-3,955
Closed -$212K – 998
2016
Q2 		$212K Buy
+3,955
New +$186K 0.01% 872

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Squarepoint's ANIK Position: Q2 2026 in Review

Squarepoint opened a new position in Anika Therapeutics (ANIK) in Q2 2026: 18,751 shares worth $274K. The stake represents ﹤0.01% of the portfolio and ranks #3877 among its holdings. This is a return to the name: Squarepoint previously reported a position in ANIK as recently as Q4 2024.

Squarepoint first reported a position in ANIK in Q2 2016 and has held it in 19 quarters since. The position peaked at $1.46M in Q4 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Squarepoint held 18,751 shares of Anika Therapeutics worth $274K as of Q2 2026.
  • Anika Therapeutics was a new Squarepoint position in Q2 2026.
  • Anika Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3877 holding.
  • Squarepoint first reported a position in Anika Therapeutics in Q2 2016 and has held it in 19 quarters since.
  • Squarepoint's Anika Therapeutics position peaked at $1.46M in Q4 2019.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.